MorphoSys AG Announces New Management Appointments

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - May 30, 2012) -

MorphoSys AG / MorphoSys Announces New Management Appointments . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has strengthened its management in two positions. Charlotte Lohmann joins the Company as General Counsel, and Martin Clark as Head of Central Purchasing & Logistics.

Charlotte Lohmann joins MorphoSys after eleven years at Wilex AG where she was most recently Senior Vice President Legal Affairs & Human Resources. Prior to her position at Wilex, she practiced as a lawyer at the law firm KPMG Treuhand & Goerdeler GmbH in Munich. She started her career in the tax and law department of the auditing company KPMG Deutsche Treuhand-Gesellschaft AG in the Munich office. Mrs. Lohmann received her degree in law from the University of Munich and is a licensed attorney.

Martin Clark joins MorphoSys from Sandoz Biopharmaceuticalswhere he managed the delivery of projects via third party contract research organizations as Head of Clinical Operations and Third Party Management. He has over 30 years experience in the pharmaceutical industry filling both scientific and management positions with Basilea, Serono, Merck-Serono, Novartis and Pfizer.

“We are very pleased to welcome outstanding individuals for two important positions within the MorphoSys Group,” explained Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. “These additions will further strengthen and complement our existing management team, and will help us to continue to build MorphoSys as a leading biopharmaceutical company.”

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company’s AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®, CysDisplay®, RapMAT® and arYla® are registered trademarks of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release (PDF): http://hugin.info/130295/R/1615757/515147.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1615757]